ZUNVEYL
Clinical safety rating: caution
Comprehensive clinical and safety monograph for ZUNVEYL (ZUNVEYL).
ZUNVEYL is a benzimidazole derivative anthelmintic that binds to β-tubulin in parasitic nematodes, inhibiting microtubule polymerization and disrupting glucose uptake, leading to energy depletion and death of the parasite.
| Metabolism | Primarily hepatic via CYP1A2 and UGT1A1; undergoes first-pass metabolism. |
| Excretion | Primarily renal excretion of unchanged drug (approx. 60-70%) and biliary/fecal elimination (approx. 20-30%). |
| Half-life | Terminal elimination half-life is approximately 12-15 hours, supporting twice-daily dosing. |
| Protein binding | Approximately 95% bound to plasma proteins, primarily albumin. |
| Volume of Distribution | Volume of distribution is approximately 0.3-0.5 L/kg, indicating moderate distribution predominantly in extracellular fluid. |
| Bioavailability | Oral bioavailability is approximately 40-50% due to first-pass metabolism. |
| Onset of Action | Oral: Onset of action occurs within 30-60 minutes post-dose. |
| Duration of Action | Duration of action is approximately 12 hours, consistent with twice-daily administration. |
ZUNVEYL (bendamustine hydrochloride) 100 mg/m² intravenously over 30 minutes on days 1 and 2 of a 28-day cycle, for up to 6 cycles.
| Dosage form | TABLET, DELAYED RELEASE |
| Renal impairment | For creatinine clearance (CrCl) 30-39 mL/min: reduce dose to 50 mg/m² on days 1 and 2. For CrCl <30 mL/min: not recommended. No adjustment for CrCl ≥40 mL/min. |
| Liver impairment | For Child-Pugh class A: no adjustment. For Child-Pugh class B: reduce dose to 50 mg/m² on days 1 and 2. For Child-Pugh class C: not recommended. |
| Pediatric use | Safety and effectiveness in pediatric patients have not been established. |
| Geriatric use | No specific dose adjustment required based on age alone; monitor renal function and hematologic toxicity closely, as elderly patients may have increased sensitivity to myelosuppression. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for ZUNVEYL (ZUNVEYL).
| Breastfeeding | Bupivacaine is excreted in human milk in small amounts. The milk-to-plasma ratio (M/P) is approximately 0.3. At therapeutic maternal doses, the estimated daily infant dose is less than 1% of the maternal dose and is unlikely to cause adverse effects in breastfed infants. However, caution is advised, especially in premature or ill infants, due to the risk of accumulation. |
| Teratogenic Risk | ZUNVEYL (bupivacaine liposome) is classified as FDA Pregnancy Category C. Animal studies have shown adverse effects on fetal development at doses similar to human doses. In the first trimester, there is a potential risk for teratogenicity, though no adequate human studies exist. In the second and third trimesters, use may be associated with fetal bradycardia, acidosis, and central nervous system depression due to placental transfer. Avoid use during pregnancy unless clearly needed. |
■ FDA Black Box Warning
None.
| Serious Effects |
["Hypersensitivity to ZUNVEYL or any benzimidazole derivatives","Severe hepatic impairment (Child-Pugh class C)","Concurrent use with systemic metronidazole (increased risk of encephalopathy)","Use in patients with known galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption (due to lactose content)"]
| Precautions | ["Bone marrow suppression (neutropenia, thrombocytopenia) - monitor CBC during prolonged therapy","Hepatotoxicity - monitor liver enzymes","Risk of metabolic acidosis in children <2 years","Seizure risk in patients with hepatic impairment","Use in pregnancy: Category C (avoid in first trimester unless potential benefit outweighs risk)"] |
Loading safety data…
| Fetal Monitoring | Monitor maternal vital signs, including heart rate and blood pressure, continuously during administration. Assess fetal heart rate patterns throughout labor if used for obstetric anesthesia. Monitor for signs of local anesthetic systemic toxicity (LAST) in the mother, including neurological and cardiovascular symptoms. In neonates, observe for respiratory depression, bradycardia, and hypotonia if given near delivery. |
| Fertility Effects | Reproductive studies in animals have not demonstrated impaired fertility at clinically relevant doses. However, no well-controlled human studies are available. Bupivacaine is not known to directly affect human spermatogenesis or oogenesis. Use of ZUNVEYL may indirectly impact fertility if used for procedures affecting reproductive organs, but no direct fertility effects have been reported. |